2016-11-11T13:45:27-07:00 2015-12-31 990 2015-01-01 264489946 SAGE BIONETWORKS SAGE 2066672102 1100 Fairview Ave N Seattle WA 98109 Lara Mangravite President 2066672102 2016-11-11 2015 2017-02-10 21:41:12Z Lara Mangravite 1100 Fairview Ave N M1-C108 Seattle WA 98109 7695817 0 X www.sagebase.org X 2009 WA Sage Bionetworks is a strategic research organization with a mission to coordinate and link academic and commercial biomedical researchers, patients and citizens through a Commons that represents a new paradigm for genomics intellectual property, researcher cooperation and contributor evolved resources. This mission has several interdependent themes, including: conducting research on network models of disease; building the computational platform for the Commons; and activating public engagement. 6 5 46 6 0 0 7808314 6230208 1552869 1464553 1802 1056 18940 0 9381925 7695817 230351 411920 0 0 5801106 5824396 0 0 54163 1412793 2142861 7444250 8379177 1937675 -683360 5497513 4810343 1005378 1001568 4492135 3808775 Sage Bionetworks is a strategic research organization with a mission to coordinate and link academic and commercial biomedical researchers, patients and citizens through a Commons that represents a new paradigm for genomics intellectual property, researcher cooperation and contributor evolved resources. This mission has several interdependent themes, including: conducting research on network models of disease; building the computational platform for the Commons; and activating public engagement. Sage Bionetworks is a non-profit research organization that seeks to develop predictors of disease and accelerate health research through the creation of open systems, incentives, and standards. We create strategies and platforms that empower researchers to share and interpret data on a colossal scale, crowdsource tests for new hypotheses, and contribute to knowledge through community challenges. 0 0 5768003 4160784 5765096 Research Communities and Challenges: Sage Bionetworks conducts research independently as well as with collaborators worldwide across a variety of disease areas. We work to redefine how complex biological data is gathered, shared and used through open systems, incentives, and norms. Our work includes the building of platforms and services and undertaking research developing predictors relating to health. In 2015, Sage was engaged in over 30 active federal research projects, and nearly 50 projects overall. Research Communities active in 2015 included the following: The AMP AD Knowledge Portal is a premier repository and workspace for multi-omic data generated through the AMP-AD consortia - a public private partnership, with the goal of accelerating the development of new drugs for the treatment and prevention of Alzheimer's disease. Data was first publically released starting in March 2015. The Colorectal Cancer Consortium is a collection of colorectal cancer researchers and data scientists from 15 academic, pharmaceutical, and non-profit partners, which represents the first effort to generate consensus cancer, subtypes, taking a major step toward precision medicine in CRC. The CommonMind Consortium is a Public-Private Pre-Competitive partnership with the goal to generate and analyze large-scale genomic data from human subjects with neuropsychiatric disease and to make this data and the analytical results broadly available. March 2015 marked the first data release. The Infectious Disease Resilience project is designed to identify common characteristics of individuals that are resilient to infectious disease as a mechanism to understand the underlying biology. The mPower Public Researcher Portal is the data access point for the mobile app-based study piloting new approaches to monitoring key indicators of Parkinson Disease progression and diagnosis. The Progenitor Cell Biology Consortium (PCBC) is an NIH sponsored effort to identify and characterize progenitor cell lineages and to develop new strategies related to the transplantation of these cells. The goal of the PsychENCODE Consortium is a public, comprehensive, and integrated resource of human brain data with a focus on autism, mood disorders, and psychoses. Data generated by the Consortium will be disseminated to the public starting in 2016. The Synodos Consortium is a first-of-its-kind Nuerofibromatosis research collaboration dedicated to defeating the rare genetic disorder neurofibromatosis type 2. With data from 12 cancers The Cancer Genome Atlas (TCGA) is an effort to simultaneously analyze molecular platforms for patterns across cancer types. Working in Synapse this group created a common data resource and made results available through 18 published papers. In 2013, Sage partnered with DREAM (http://www.the-dream-project.org/), to host open computational challenges designed and run by a community of researchers from a variety of organizations, and with a solver community of more than 15,000 individuals. DREAM Challenges invite participants to propose solutions to fundamental questions about systems biology and translational medicine - fostering collaboration and building communities in the process. Sage's Challenges leverage the "wisdom of the crowd" to find new and better computational models and make these methods available to all. Active Challenges in 2015 included ALS Stratification Prize4Life DREAM Challenge - focuses on predicting the progression and survival of ALS patients. This effort will also work to significantly reduce the costs of future ALS clinical trials, aid clinical care and identify new disease predictors that can lead to novel biomarker development. AstraZeneca Drug Combination Prediction DREAM Challenge - designed to explore fundamental traits that underlie effective combination treatments and synergistic drug behavior using baseline genomic data. ICGC-TCGA Somatic Mutation Calling -Tumor Heterogeneity DREAM Challenge - an international effort to improve standard methods for subclonal reconstruction to quantify and genotype each individual cell population present within a tumor. 1980883 0 1661123 Sage Bionetworks Mobile Health (mHealth): In 2013, Sage expanded efforts in citizen engagement with the development of Bridge, a cloud-based collaborative science platform designed to incorporate open data, patient wisdom and public involvement into biomedical research. Bridge is a key piece of IT infrastructure essential for empowering citizens to share and track their data, to partner on research and to fund the projects that matter most to them. On Bridge, citizens, patients and researchers are able to use online tools that connect people, their data and their stories to build online communities focused on defining the disease or health research that matters most to patients and their families. With the 2015 launch of Apple's open source ResearchKit platform, Sage Bionetworks has been an integral partner in the design, development and launch of smartphone-enabled clinical studies across multiple disease areas. mHealth services include: software engineering for app design and development, data governance for e-consent and IRB submission and IRB-approved cloud-based infrastructure (Bridge Server) for study data collection, de-identification and hosting. In 2015, Sage launched the first two mobile app-based research studies on Bridge as part of Apple's ResearchKit. Enrollment in the Parkinson's mPower Study and the Share the Journey Breast Cancer Survivor Study opened in March 2015. The Parkinson's mPower Study uses microphone, accelerometer, and touch-screen sensors in a mobile app to measure fluctuations in gait, posture, voice, and manual dexterity, and explores correlations with environmental factors such as sleep and exercise. The Share the Journey Breast Cancer Survivor Study is designed to look at the long-term side effects of chemotherapy on mood, cognitive function, and energy level, exploring the intersection of these experiences with environmental factors to learn how symptoms can be more effectively managed. Active Challenges in 2015 included:ALS Stratification Prize4Life DREAM Challenge - focuses on predicting the progression and survival of ALS patients. This effort will also work to significantly reduce the costs of future ALS clinical trials, aid clinical care and identify new disease predictors that can lead to novel biomarker development. AstraZeneca Drug Combination Prediction DREAM Challenge - designed to explore fundamental traits that underlie effective combination treatments and synergistic drug behavior using baseline genomic data. ICGC-TCGA Somatic Mutation Calling -Tumor Heterogeneity DREAM Challenge - an international effort to improve standard methods for subclonal reconstruction to quantify and genotype each individual cell population present within a tumor. 0 0 0 7748886 1 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 1 0 0 0 1 1 0 0 0 0 0 1 0 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 1 5 0 46 1 0 0 0 0 0 0 0 0 0 0 X 6 5 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 0 1 0 0 X Diane Gary 2066673038 1100 Fairview Ave N Seattle WA 98109 Stephen Friend President/Director 50 0 X X 240416 0 15122 Eric Schadt Director/Chair of Scientific Advisory Board 1 0 X 0 0 0 Jeff Hammerbacher Director 1 0 X 0 0 0 Tony Ford-Hutchinson Director 1 0 X 0 0 0 Gustavo Stolovitsky Director 1 0 X 0 0 0 Eric Topol Director 1 0 X 0 0 0 Diane Gary Secretary 50 0 X 156025 0 25961 Mike Kellen Director, Technology & Software Development 50 0 X 182601 0 23773 John Wilbanks Chief Commons Officer 50 0 X 220325 0 34228 Thea Norman Director, Strategic Development 50 0 X 170523 0 34557 Lara Mangravite Director, Systems Biology 50 0 X 160948 0 28770 Arno Klein Principal Scientist 50 0 X 153991 0 19351 Justin Guinney Director, Oncology 50 0 X 152542 0 30769 1437371 0 212531 26 0 1 0 0 0 0 0 0 3549664 2680544 93459 6230208 Collaborators 541711 1464553 1464553 0 0 0 0 0 0 1464553 1056 0 0 1056 0 0 0 0 0 0 0 0 0 0 0 0 0 0 7695817 1464553 0 1056 X 331398 331398 0 0 80522 80522 0 0 677878 391657 270249 15972 0 0 0 0 4423427 4229511 168628 25288 287842 267039 20247 556 149728 120122 24400 5206 285521 260620 24193 708 68057 61891 5636 530 119533 119533 0 0 34654 34654 0 0 0 0 0 0 0 0 0 0 0 0 1111552 1110740 742 70 588 588 0 0 28208 25652 2336 220 52752 48480 3905 367 0 0 0 0 374786 340833 31035 2918 237411 216386 19218 1807 0 0 0 0 24772 22528 2051 193 0 0 0 0 0 0 0 0 9083 8260 752 71 19807 18013 1640 154 61658 60459 1096 103 8379177 7748886 576128 54163 0 0 1987176 866729 3319126 3509569 79316 367983 42277 0 0 0 0 0 0 0 29074 54082 62146 50166 40544 11980 0 0 0 0 0 0 0 0 0 0 5497513 4810343 496748 490503 0 0 508630 511065 0 0 0 0 0 0 0 0 0 0 0 1005378 1001568 X 814142 361382 3677993 3447393 0 0 4492135 3808775 5497513 4810343 -683360 0 0 0 0 0 X 1 X 1 X 1 1 1 X 3717790 5014681 5154616 7808314 6230203 27925604 0 0 0 0 0 0 0 0 0 0 0 0 3717790 5014681 5154616 7808314 6230203 27925604 0 27925604 1702 3146 1640 1802 1056 9346 0 0 0 0 0 0 2088987 1766523 1531308 1552869 1464542 8404229 36339179 0 0.76847 0.7018 X Schedule A, Part II, Line 10 Fee for Service Revenue from research collaborations. RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 0 0 0 0 0 0 0 0 0 0 0 62146 0 50166 11980 0 0 0 0 11980 7695817 0 0 0 0 0 7695817 0 0 0 7695817 8379177 0 0 0 0 0 8379177 0 0 0 8379177 1 Europe (including Iceland and Greenland) 0 0 Grantmaking Data generation for our Coordinated Pediatric AML Treatment Options project. 80522 0 0 80522 Europe (including Iceland and Greenland) Data generation for our Coordinated Pediatric AML Treatment Options project. 80522 Electronic Fund Transfer 0 0 1 0 0 0 0 0 0 Schedule F, Part I, Line 2 Monitoring the use of grant funds: In some cases, grants received by Sage Bionetworks are passed on to sub-recipients through a sub-award agreement. The Grant Manager is responsible for initiating the sub-award agreement after obtaining budget approval from the PI and Operations Director. In issuing a sub-award, the Grant Manager is responsible for: obtaining verification of the sub-awardee's facilities and administrative rates and Single Audit Reports; reviewing the prime award special terms and conditions to determine whether they are applicable to the sub-award; and determining whether the sub-awardee meets all of the other administrative and regulatory requirements of the prime award. Once the sub-award has been issued, the Grant Manager is responsible for monitoring sub-award activity, including compliance with all reporting requirements. The Grant Manager is also responsible for forwarding the fully executed sub-award documents to the Accounting Manager to ensure proper billing. Payments are made only after the sub-award agreement has been fully executed by both parties. 1 Fred Hutchinson Cancer Research Center 1100 Fairview Ave N Seattle WA 98109 237156071 62887 Assist in the high throughput drug screening and genomic profiling of patients at relapse to define patient specific drug sensitivity profile and their genomic/transcript composition for our Coordinated Pediatric AML Treatment Options project. Oregon Health Sciences University 3181 SW Sam Jackson Park Rd Portland OR 97239 931176109 100166 Validate and assimilate data from functional and genomic data to facilitate their use in the cancer cloud hub, provide bioinformatics analyses and algorithm design to aid in the development of real-time models to predict treatment outcomes based on integrated data for each patient for our Coordinated Pediatric AML Treatment Options project. Phoenix Children's Hospital 1919 E Thomas Road Phoenix AZ 85016 742421549 93967 Perform drug screening, molecular integration of data and clinical trial development as well as analysis and transfer of the large genomic data sets that will be integrated by the bioinformatical teams at each participating institution for our Coordinated Pediatric AML Treatment Options project. Institute for Medical Research Inc 508 Fulton St Durham NC 27705 561655431 49295 Project development, data curation, pilot analyses, develop open innovation challenge to crowd source study design, and build a collaborative working group from participants and organizers for our "Resilience to Infection: an open innovation challenge to the community" project. University of South Alabama 307 N University Blvd No 130 Mobile AL 36608 630477348 13334 Provide data analyses for our "Resilience to Infection: an open innovation challenge to the community" project. Group Health Research Institute 1730 Minor Ave Suite 1600 Seattle WA 98101 910511770 11749 Data/image generation for our Digital Mammography Challenge project. 6 0 Schedule I, Part I, Line 2 In 2015, Sage Bionetworks issued grants, contributions, and prizes. Contributions were given in support of an awarded institution's project and prizes were awarded to research challenge winners. Monitoring the use of grant funds: In some cases, grants received by Sage Bionetworks are passed on to sub-recipients through a sub-award agreement. The Grant Manager is responsible for initiating the sub-award agreement after obtaining budget approval from the PI and Operations Director. In issuing a sub-award, the Grant Manager is responsible for: obtaining verification of the sub-awardee's facilities and administrative rates and Single Audit Reports; reviewing the prime award special terms and conditions to determine whether they are applicable to the sub-award; and determining whether the sub-awardee meets all of the other administrative and regulatory requirements of the prime award. Once the sub-award has been issued, the Grant Manager is responsible for monitoring sub-award activity, including compliance with all reporting requirements. The Grant Manager is also responsible for forwarding the fully executed sub-award documents to the Accounting Manager to ensure proper billing. Payments are made only after the sub-award agreement has been fully executed by both parties. X 1 1 X 0 0 0 0 0 0 0 0 0 Stephen Friend President/Director 240416 0 0 0 0 0 0 0 15122 0 255538 0 0 0 John Wilbanks Chief Commons Officer 220325 0 0 0 0 0 0 0 34228 0 254553 0 0 0 Mike Kellen Director, Technology & Software Development 182601 0 0 0 0 0 0 0 23773 0 206374 0 0 0 Thea Norman Director, Strategic Development 170523 0 0 0 0 0 0 0 34557 0 205080 0 0 0 Lara Mangravite Director, Systems Biology 160948 0 0 0 0 0 0 0 28770 0 189718 0 0 0 Justin Guinney Director, Oncology 152542 0 0 0 0 0 0 0 30769 0 183311 0 0 0 Diane Gary Secretary 156025 0 0 0 0 0 0 0 25961 0 181986 0 0 0 Arno Klein Principal Scientist 153991 0 0 0 0 0 0 0 19351 0 173342 0 0 0 Schedule J, Part I, Line 1a All travel is conducted per the company travel policy. Schedule J, Part I, Line 3 Setting executive compensation is the responsibility of the Board of Directors Compensation Committee. 0 0 0 0 Schedule M, Part I, Line 33 Received In-Kind legal services. Form 990, Part VI, Section B, Line 11b The 990 is reviewed by the company's Director of Operations and President prior to filing. Form 990, Part VI, Section B, Line 12c Sage Bionetworks has a Financial Conflict of Interest Policy (FCOI) that complies with the National Institutes of Health-specific requirements promoting objectivity in research, 42 CFR Part 50 subpart F. On an annual basis, Sage Bionetworks Officers, Directors and members of committees of the Board of Directors authorized to act on behalf of the board, and employees designated by the President of Sage Bionetworks, including any employees serving as an investigator on a federal/Public Health Services award, must complete the Sage Bionetworks Annual Conflict of Interest Questionnaire. New Employees serving as investigators are required to complete a FCOI form within 30 days of their start date. In addition, all investigators must submit an ad hoc disclosure of any Significant Financial Interest they acquire or discover during the course of the year within 30 days of discovering or acquiring the Significant Financial Interest. Any reported conflicts are reviewed by the President and outside counsel. Form 990, Part VI, Section B, Line 15 Executive compensation was set by the Board of Directors Compensation Committee. Form 990, Part VI, Section C, Line 19 The organization's financials are contained within its 990 returns. These returns are available to the public through organizations such as Guidestar, dedicated to publicizing information about nonprofit organizations. The organization's governing documents and conflict of interest policies are available upon request. Form 990, Part IX, Line 11g Scientific Research Expenses $210,864; Commons/Assembly Expenses $570,971; Platform/Scientific Computing Expenses $298,770; Professional Services/Accounting $25,547; Fund Development $5,400